New allosteric inhibitors of cholesterol synthesis – an alternative to statins?
Statins reduce cholesterol levels in the body by acting as competitive inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase – the enzyme that catalyses cholesterol biosynthesis. But some patients don’t respond to statins and catalytic anti-oxidants have an advantage over statins: in their dual mode of action, they also reduce free radicals in the body.
The scientists showed that the catalytic antioxidant, Fe-1, and its analogues, inhibit HMG-CoA reductase in a different way to statins. They propose that the amphipolar nature of the drug macrocycles is important for binding to an allosteric site of HMG-coA reductase and inhibiting the enzyme’s catalytic activity.
Most read news
Original publication
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.